• Investing in biodefense companies, II

    Billions of dollars are being spent on finding vaccines and treatments for possible bioterror attacks; investment analyst says that these billions of dollars in government spending notwithstanding, when considering an investment in a company doing R&D in the bioterror field, you should consider its non-terror-related biotechnology efforts, and the quality of its management team

  • Universal biosensor would detect disease, bioterror attack, pollution

    A consortium of U.K. research institutions, in collaboration with a Chinese University, work on developing a universal biosensor which would help in many types of detection — from home diagnosis of disease to chemical plant monitoring, anti-bioterrorism, and pandemic outbreak

  • Why it takes so long to trace a bad tomato

    Tomatoes do not carry bar codes, so it is difficult to trace the source of the recent tomato-borne salmonella outbreak; tomatoes coming from Mexico and parts of Florida are prime suspects

  • New bird flu vaccine looks promising

    Baxter’s cell-based vaccine appears to work better than more traditional egg-based ones; tests show promise at low doses

  • Making U.S. food safe, I: FDA not moving fast enough

    The recent outbreak of tomatoe-borne salmonella poisoning moved legislators to charge that the FDA has not made good on its promise last year to make food safer for U.S. consumers

  • Background: More on tomato-borne salmonella

    Recent census of produce outbreaks between 1996 and 2007 counted no fewer than 33 epidemics from Salmonella-contaminated fruits and vegetables; in five of them, tomatoes were the culprit

  • FDA warns of tomatoe-bornes almonellosis

    The Food and Drug Administration warns U.S consumers, restaurants of salmonella poisioning causes by three types oftomatoes; 145 cases reported, with 23 requiring hospitalization

  • Tom Daschle calls for greater U.S.-U.K. bioterror cooperation

    Daschle: “The threat of bioterrorism will increase exponentially because biological agents used to carry out such attacks will continue to become more accessible and more technologically advanced”

  • Investing in biodefense companies

    Billions of dollars are pouring into biodefense vaccines and treatments; do companies engaged in developing such vaccines and treatment offer attractive investment opportunities? The answer is a qualified “Yes” to this specific question — but a more resounding “Yes” when these companies’ other research and development endeavors are taken into consideration

  • Tyson destroys 15,000 chicken infected with H7N3

    Arkansas poultry giant destroys 15,000 hens after routine tests discover antibodies to H7N3, a mild strain of avian flu; company says there is no threat to humans

  • OSHA issues guidance regarding storage of face masks, respirators

    OSHA requests comments on proposed guidance on workplace stockpiling of respirators and face masks for pandemic influenza

  • Avian flu by the numbers

    Two Los Alamos National Laboratory theorists have developed a mathematical tool which could help health experts and crisis managers determine in real time whether an emerging infectious disease such as avian influenza H5N1 is poised to spread globally

  • Nanotechnology-based biosensor

    NASA develops nanotechnology-based biosensor that can detect trace amounts of specific bacteria, viruses, and parasites; New York-based Early Warning, Inc. will initially market the sensor to water treatment facilities, food and beverage companies, industrial plants, hospitals, and airlines

  • Boston biolab: Panel urges review of possible lab threats

    As community opposition to the almost-complete Boston University biolab continues, a panel of experts says neighborhood’s concerns — and safety — should not be excluded from consideration of final approval for lab opening

  • CDC biolab not ready after 2 1/2 years

    A new CDC biosafety lab was supposed to open in the fall of 2005; it is still not open, and legislators begin to wonder why; they note that at the University of Texas Medical Branch in Galveston, it took less than seven months for its BSL-4 lab to become operational after construction was finished